EBOS this morning reported its results for the six months to 31 Dec, with net profit after tax rising 10.9% to NZ$68.8 million.
The company said its Australian revenues climbed 27%, resulting in EBITDA growth of 11%.
The increased sales were driven by the full six months of trading for the new Hepatitis C medicines.
"In the Australian pharmacy market, wholesale revenue growth (excluding Hepatitis C medicines) was affected by the ongoing impact of PBS reforms and lower levels of activity in the non-prescription over-the counter (OTC) channel," said EBOS Group ceo Patrick Davies.
However the company's Healthcare division continues to offset the negative impact of PBS reforms "by expanding its revenue streams and generating cost savings and improved productivity across its operations," he added.
The group's Consumer Products division saw revenue surge 58% year-on-year, with a full six month contribution from Red Seal which was acquired on 30 Nov 2015.
Davies said EBOS was continuing to invest in its healthcare businesses, citing the completion of the Terry White Chemmart merger in the first half.
"This merger has created one of Australia's largest retail pharmacy networks that is well placed for growth and future opportunities that emerge in the retail pharamcy sector," he commented.
Other investments in the EBOS operational capacity include the $58m new wholesale distribution facility in Brisbane, and the development of a new contract logistics site in Sydney.
EBOS said it expects its full year FY17 earnings to be close to 10% higher than the prior year.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Feb 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Feb 17